The use of biomarkers in the evaluation of the initial transition to heart failure from arterial hypertension

摘要

The present invention is, in a subject carrying the risk factors for developing heart failure, a method of diagnosing abnormality of function and / or structure of the heart prior to heart failure, said method comprising the steps of: a) a obtained from the individual in sample, measuring the concentration of at least one cardiac troponin; concentration measured with and c) step (a); b) optionally, measuring the concentration of one or more other heart failure markers in the sample and optionally step (b) is concentration measured in (s), by comparing the concentration of established this marker or these markers in a control sample, to evaluate abnormalities of the function and / or structure. The present invention also provides a method of object carrying the risk factors for developing heart failure predicting the risk of suffering from heart failure, said method comprising the steps of: a) a in a sample obtained from the individual, at least one measuring the concentration of cardiac troponin; b) optionally, measuring the concentration of one or more other heart failure markers in the sample; and c) step (step optionally concentration and measured in a) (b) in the measured concentration (s), by comparing the concentration of established this marker or these markers in a control sample, predicting the risk of a subject suffering from heart failure. The method is further characterized in that one or more other marker of said is selected from the group consisting cardiac troponin marker, from GDF-15 and insulin growth factor binding protein (IGFBP7). In a preferred embodiment of the present invention, the subject is suffering from left ventricular diastolic dysfunction. The present invention also relates to a method of determining a treatment of a subject carrying a risk factor for developing heart failure, and to a method of monitoring the treatment. In a preferred embodiment of the present invention, at least one other marker is selected cardiac troponin, from GDF-15 and IGFBP7. The present invention further provides a method of monitoring the abnormality of the treatment of functional and / or structural heart prior to heart failure in a subject, said method comprising the steps of: a) a in at least one sample of the subject, at least 1 the concentration of the types of cardiac troponin, repeated measures within a specific time interval; b) optionally, measuring the concentration of one or more other heart failure markers in the sample; measured at and c) step (a) in one or more of the markers set forth in and c) above; with the concentration and if the concentration measured in step (b) by (s), compared to the concentration of that established this marker or these markers in a control sample based on the difference between the measured concentration, the object is evaluated whether the change has occurred in the pathophysiological state. .FIELD 1